Tags

Type your tag names separated by a space and hit enter

Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors.
J Clin Endocrinol Metab. 1981 Dec; 53(6):1285-7.JC

Abstract

It has recently been proposed that nomifensine (Nom) administration discriminates those patients with PRL-secreting pituitary tumors from those who have hyperprolactinemia due to other causes. In the present study, this test was performed on 12 presumed functional hyperprolactinemic subjects, 9 patients with surgically proved PRL-secreting pituitary adenoma (6 microadenoma and 3 macroadenoma), and 7 patients with surgically proved non-PRL-secreting hypothalamic tumors (3 craniopharyngioma, 3 suprasellar germinoma, and 1 suprasellar ependymoma). The Nom test suppressed the plasma PRL level to below 60% of the basal level in all 12 women with presumed functional hyperprolactinemia, but did not alter plasma PRL levels in the patients with PRL-secreting pituitary adenoma or hypothalamic tumor. This evidence confirms that the test is, at least in part, able to discriminate those individuals with PRL-secreting pituitary adenoma from those without, regardless of the size of the tumor. However, the test is not capable of distinguishing between hyperprolactinemia due to PRL-secreting pituitary tumors and that due to non-PRL-secreting hypothalamic tumors. A lack of response to Nom is not necessarily due to the presence of a PRL-secreting tumor, and may be related to dysfunction to the hypothalamic-pituitary system.

Authors

No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article

Language

eng

PubMed ID

7298805

Citation

Kamoi, K, et al. "Comparison of the Responses in the Nomifensine Test With Hyperprolactinemia Due to Prolactin-secreting Pituitary Tumors and Nonprolactin-secreting Hypothalamic Tumors." The Journal of Clinical Endocrinology and Metabolism, vol. 53, no. 6, 1981, pp. 1285-7.
Kamoi K, Tchuchida I, Sato H, et al. Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors. J Clin Endocrinol Metab. 1981;53(6):1285-7.
Kamoi, K., Tchuchida, I., Sato, H., Tanaka, R., Ishiguro, T., Kaneko, K., Iwasaki, Y., & Shibata, A. (1981). Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors. The Journal of Clinical Endocrinology and Metabolism, 53(6), 1285-7.
Kamoi K, et al. Comparison of the Responses in the Nomifensine Test With Hyperprolactinemia Due to Prolactin-secreting Pituitary Tumors and Nonprolactin-secreting Hypothalamic Tumors. J Clin Endocrinol Metab. 1981;53(6):1285-7. PubMed PMID: 7298805.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Comparison of the responses in the nomifensine test with hyperprolactinemia due to prolactin-secreting pituitary tumors and nonprolactin-secreting hypothalamic tumors. AU - Kamoi,K, AU - Tchuchida,I, AU - Sato,H, AU - Tanaka,R, AU - Ishiguro,T, AU - Kaneko,K, AU - Iwasaki,Y, AU - Shibata,A, PY - 1981/12/1/pubmed PY - 1981/12/1/medline PY - 1981/12/1/entrez SP - 1285 EP - 7 JF - The Journal of clinical endocrinology and metabolism JO - J Clin Endocrinol Metab VL - 53 IS - 6 N2 - It has recently been proposed that nomifensine (Nom) administration discriminates those patients with PRL-secreting pituitary tumors from those who have hyperprolactinemia due to other causes. In the present study, this test was performed on 12 presumed functional hyperprolactinemic subjects, 9 patients with surgically proved PRL-secreting pituitary adenoma (6 microadenoma and 3 macroadenoma), and 7 patients with surgically proved non-PRL-secreting hypothalamic tumors (3 craniopharyngioma, 3 suprasellar germinoma, and 1 suprasellar ependymoma). The Nom test suppressed the plasma PRL level to below 60% of the basal level in all 12 women with presumed functional hyperprolactinemia, but did not alter plasma PRL levels in the patients with PRL-secreting pituitary adenoma or hypothalamic tumor. This evidence confirms that the test is, at least in part, able to discriminate those individuals with PRL-secreting pituitary adenoma from those without, regardless of the size of the tumor. However, the test is not capable of distinguishing between hyperprolactinemia due to PRL-secreting pituitary tumors and that due to non-PRL-secreting hypothalamic tumors. A lack of response to Nom is not necessarily due to the presence of a PRL-secreting tumor, and may be related to dysfunction to the hypothalamic-pituitary system. SN - 0021-972X UR - https://www.unboundmedicine.com/medline/citation/7298805/Comparison_of_the_responses_in_the_nomifensine_test_with_hyperprolactinemia_due_to_prolactin_secreting_pituitary_tumors_and_nonprolactin_secreting_hypothalamic_tumors_ L2 - https://academic.oup.com/jcem/article-lookup/doi/10.1210/jcem-53-6-1285 DB - PRIME DP - Unbound Medicine ER -